1Zoulim F, Darmaoui E and Trepo C. Inhibitory effect of penciclovir on the priming of hepadnavirus revers transcription. Abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. Washington,DC: American Society Microbiology, 1995:182
2Shaw T and Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantionmers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology, 1996, 24(5) :996-1002
3Gill KS and Wood MJ. The clinical pharmacokinetics of famciclovir. Clin phamacokinet, 1996,31(1): 1 - 8
4Crumpacker C. The pharmacological profile of famciclovir. Semim Dematol,1996,15(2 Suppl 1 ): 14 - 26
5Stott GA.Famciclovir:a new systemic antiviral agent for herpesvirus infections. Am Fam Physician, 1997,55(7) :2501 - 4
6Christian Trepo. AASLD conference in Chicago Nov,ii,1996
7Main J, Brown JL, Howells C, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepatol, 1996,3(4):211- 5
8Singh N, Gayowski T, Wannstedt CF, et al. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation.Transplantation, 1997,63(10): 1415 - 9
9Klein M, Geoghegan J and Schmidt K. Conversion of recurrent delta-positive hepatitis B infection to seronegativity with famciclovir after liver transplantation. Transplantation, 1997,64( 1 ): 162 - 3
10Lau GKK,Liang R,Wu PC,et al. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogenic bone marrow transplantation. J hepatol, 1998,28(2) :359 - 368
